Transdermal granisetron

Drugs

Volumn 69, Issue 18, 2009, Pages 2597-2605

  Duggan, Sean T ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; DEXAMETHASONE; GRANISETRON; KETOCONAZOLE; PHENOBARBITAL; SANCUSO; UNCLASSIFIED DRUG;

APPLICATION SITE ERYTHEMA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; EMBASE; HEADACHE; HUMAN; MEDLINE; NAUSEA; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MOLECULAR STRUCTURE; NAUSEA; RECEPTORS, NEUROKININ-1; RECEPTORS, SEROTONIN; REMISSION INDUCTION; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 71849117644     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202780-000000000-00000     Document Type: Review

References (20)

1. National Comprehensive Cancer Network®. NCCN Clin-ical Practice Guideline in Oncology™: antiemeis (v. 3. 2009) [online]. Available from URL: http://www.nccn.org/ professionals/physician-gls/PDF/antiemesis.pdf [Accessed 2009 Aug 10].
2. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008 Mar-Apr; 14 (2): 85-93.
3. Antonopoulos MS, Caspi A. Product profiler: Sancuso® (Granisetron transdermal delivery system): a new formulation for chemotherapy-induced nausea and vomiting. Pharmacy and Therapeutics 2008; 33 (10 Pt. 2): 2-27.
4. Navari RM. Pharmacological management of chemother-apy-induced nausea and vomiting: focus on recent developments. Drugs 2009; 69 (5): 515-533
5. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008 Jun 5; 358 (23): 2482-2494
6. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006 Jun 20; 24 (18): 2932-2947
7. A granisetron patch (Sancuso). Med Lett Drugs Ther 2008 Dec 15-29; 50 (1301-1302): 103-104
8. ProStrakan Inc. Sancuso® (granisetron transdermal sys-tem): US prescribing information. Bedminster: ProStrakan Inc. [online]. Available from URL: http://www.prostrakan-usa.com/PDFs/SANCUSO-Full-PI.pdf [Accessed 2009 Jul 30].
9. Nitti VW, Sanders S, Staskin DR, et al. Transdermal deliv-ery of drugs for urologic applications: basic principles and applications. Urology 2006 Apr; 67 (4): 657-664
10. Yarker YE, McTavish D. Granisetron: an update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994; 48 (5): 761-793
11. Plosker GL, Goa KL. Granisetron: a review of its pharma-cological properties and therapeutic use as an antiemetic. Drugs 1991; 42 (5): 805-824
12. Howell J, Smeets J, Drenth H, et al. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Prac. Epub 2009 Mar 20.
13. Howell J, Clark G, Yellowlees A, et al. Efficacy, safety and tolerability of a transdermal granisetron patch for prevention of single-dose chemotherapy-induced nausea and vomiting: phase II trial results [abstract no. 27]. J Oncol Pharm Pract 2009; 15 (2 Suppl.): 20. Plus poster presented at the Hematology/Oncology Pharmacy Association Annual Meeting; 2009 Jun 17-20; Miami (FL).
14. Howell J, Yellowlees A, Gutierrez-Esteinou R. Efficacy, safety and tolerability of transdermal granisetron patch for prevention of multi-day chemotherapy-induced nausea and vomiting: phase III trial results [abstract no. PA-04]. J Support Oncol 2008; 6: 335. Plus poster presented at the Fourth Annual Chicago Supportive Oncology Conference; 2008 Oct 15-18; Chicago (IL).
15. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998; 55 (2): 173-189
16. Gill D, Howell J. Pharmacokinetics and bioavailability of transdermal granisetron after a 6-day application of three patch sizes, compared with 2mg once-daily oral dose of granisetron for 5 days [abstract no. 28]. J Oncol Pharm Pract 2009; 15 (2 Suppl.): 20. Plus poster presented at the Hematology/Oncology Pharmacy Association Annual Meeting; 2009 Jun 17-20; Miami (FL).
17. Roche Laboratories Inc. Kytril (granisetron hydrochloride) tablets and oral solution: US prescribing information. New Jersey: Roche Laboratories Inc. [online]. Available from URL: http://www.rocheusa.com/products/kytril/pi- tablets. pdf [Accessed 2009 Aug 27].
18. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997 Jan; 15 (1): 103-109
19. Gutierrez-Esteinou R, Howell J, Clark G, et al. Assessment of skin irritation and sensitization potential of a transder-mal granisetron patch [abstract no. 30]. J Oncol Pharm Pract 2009; 15 (2 Suppl.): 21. Plus poster presented at the Hematology/Oncology Pharmacy Association Annual Meeting; 2009 Jun 17-20; Miami (FL).
20. US FDA. Approved drug products with therapeutic equivalence evaluations 29th edition [online]. Available from URL: http://www.fda.gov/Drugs/default.htm [Accessed 2009 Aug 20]